All Stories

  1. Response: Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients? Reply Letter to Capuano et al. (Letter to the Editor: Voclosporin in Late Onset Lupus Nephritis with Anti-PLA2R Antibodies)

    Article • Seminars in Arthritis and Rheumatism, December 2025, Elsevier

    Dr. Zahi Touma, Dr. Dafna D Gladman

  2. Reply

    Article • Arthritis Care & Research, November 2025, Wiley

    Dr. Dafna D Gladman

  3. Challenges in the therapeutic management of psoriatic arthritis

    Article • The Lancet Rheumatology, November 2025, Elsevier

    Dr. Dafna D Gladman

  4. Updates on Recent Advances in the Therapy of Adult Psoriatic Disease

    Article • Current Rheumatology Reviews, November 2025, Bentham Science Publishers

    Dr. Dafna D Gladman

  5. Changes in weight associated with tumor necrosis factor inhibition in psoriatic arthritis: results from a retrospective cohort study

    Article • Clinical Rheumatology, October 2025, Springer Science + Business Media

    Dr. Dafna D Gladman

  6. Understanding the drivers of BASDAI and back pain scores in psoriatic arthritis

    Article • Annals of the Rheumatic Diseases, October 2025, Elsevier

    Dr. Dafna D Gladman

  7. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update

    Article • Annals of the Rheumatic Diseases, October 2025, Elsevier

    Dr. Dafna D Gladman

  8. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2024 Annual Meeting

    Article • The Journal of Rheumatology, October 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  9. Membranous Lupus Nephritis: Too Little, Too Much!

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  10. Genetics of Childhood‐Onset Systemic Lupus Erythematosus

    Article • Arthritis & Rheumatology, September 2025, Wiley

    Dr. Dafna D Gladman

  11. Is antimalarial use associated with a reduced risk of LN in patients with SLE? Results from an inception cohort-based study

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  12. Venous thromboembolism in patients with lupus nephritis: frequency and risk factors—a cohort study

    Article • Rheumatology, September 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  13. Incidence and Predictors of Secondary Failure to Biologic Therapy in Patients With Psoriatic Arthritis

    Article • The Journal of Rheumatology, September 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  14. Composite Outcome Measures for Psoriatic Arthritis: Project Updates 2024

    Article • The Journal of Rheumatology, August 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  15. Cervical Lymphadenitis in a Patient Receiving Tumor Necrosis Factor Inhibitor Therapy

    Article • The Journal of Rheumatology, August 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  16. Association of Elevated Serum S100A8 / A9 Levels and Cognitive Impairment in Patients With Systemic Lupus Erythematosus

    Article • Arthritis Care & Research, August 2025, Wiley

    Dr. Dafna D Gladman

  17. Update on the Axial Involvement in Psoriatic Arthritis (AXIS) Project

    Article • The Journal of Rheumatology, August 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  18. Does baseline nephrotic range proteinuria determine the long-term outcomes of membranous lupus nephritis patients?

    Article • Seminars in Arthritis and Rheumatism, August 2025, Elsevier

    Dr. Zahi Touma, Dr. Dafna D Gladman

  19. Defining On-Treatment Remission in Plaque Psoriasis

    Article • JAMA Dermatology, August 2025, American Medical Association (AMA)

    Dr. Dafna D Gladman

  20. Predicting anxiety and depression in systemic lupus erythematosus: the role of inflammation, sociodemographic variables and clinical factors

    Article • Seminars in Arthritis and Rheumatism, August 2025, Elsevier

    Dr. Dafna D Gladman

  21. Does the time to the onset of lupus nephritis impact renal disease presentation and outcomes?

    Article • Seminars in Arthritis and Rheumatism, August 2025, Elsevier

    Dr. Dafna D Gladman

  22. Comparative Analysis of Damage Accrual in Lupus Nephritis Stratified by Biological Sex

    Article • The Journal of Rheumatology, July 2025, The Journal of Rheumatology

    Dr. Zahi Touma, Dr. Dafna D Gladman

  23. Comparison of Lupus Nephritis Onset Before and After Age 50: Effect on Presentation and Outcomes in an Inception Cohort

    Article • The Journal of Rheumatology, July 2025, The Journal of Rheumatology

    Dr. Zahi Touma, Dr. Dafna D Gladman

  24. Towards a minimal core dataset for systemic lupus erythematosus studies

    Article • Lupus Science & Medicine, July 2025, BMJ

    Dr. Dafna D Gladman

  25. ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations

    Article • The Lancet Rheumatology, July 2025, Elsevier

    Dr. Dafna D Gladman

  26. Identification of miR‐190a‐5p and miR‐26b‐5p as Potential microRNA Biomarkers for Psoriatic Arthritis

    Article • ACR Open Rheumatology, June 2025, Wiley

    Dr. Dafna D Gladman

  27. Serum Albumin as an Early Predictor of Proteinuria Recovery in Lupus Nephritis

    Article • Mediterranean Journal of Rheumatology, June 2025, PCO Convin

    Dr. Dafna D Gladman

  28. Tuft resorption in patients with psoriatic arthritis

    Article • Seminars in Arthritis and Rheumatism, June 2025, Elsevier

    Dr. Dafna D Gladman

  29. Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

    Article • Seminars in Arthritis and Rheumatism, June 2025, Elsevier

    Dr. Dafna D Gladman

  30. Functional work disability from the perspectives of persons with systemic lupus erythematosus: a qualitative thematic analysis

    Article • Arthritis Research & Therapy, May 2025, Springer Science + Business Media

    Dr. Dafna D Gladman

  31. Exploring the impact of conventional and targeted DMARDs on body weight in patients with PsA

    Article • Rheumatology, May 2025, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  32. The lack of association between cumulative MTX dose and liver fibrosis in PsA: a cohort study

    Article • Rheumatology, May 2025, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  33. Combining Clinical, Genetic and Protein Markers Using Machine Learning Models Discriminates Psoriatic Arthritis Patients From Those With Psoriasis

    Article • Journal of Psoriasis and Psoriatic Arthritis, May 2025, SAGE Publications

    Dr. Dafna D Gladman

  34. Association of Higher Levels of High‐Sensitivity C‐Reactive Protein With Future Development of Psoriatic Arthritis in Psoriasis: A Prospective Cohort Study

    Article • Arthritis Care & Research, May 2025, Wiley

    Dr. Dafna D Gladman

  35. The Road to a New Horizon in Psoriatic Arthritis

    Article • The Journal of Rheumatology, May 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  36. Identification of distinct disease activity trajectories in patients with psoriatic arthritis receiving tofacitinib: a post hoc analysis of two phase 3 studies

    Article • RMD Open, May 2025, BMJ

    Dr. Dafna D Gladman

  37. Responsive and monophasic lupus nephritis: prevalence, associations, and outcomes

    Article • Rheumatology, April 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  38. The association between cigarette smoking and radiographic progression in Psoriatic Arthritis

    Article • Seminars in Arthritis and Rheumatism, April 2025, Elsevier

    Dr. Dafna D Gladman

  39. Comparative analysis of disease outcomes: Early vs. late transition from psoriasis to psoriatic arthritis

    Article • Seminars in Arthritis and Rheumatism, April 2025, Elsevier

    Dr. Dafna D Gladman

  40. Association Between Metabolic Syndrome and Radiographic Changes in Psoriatic Arthritis: A Cohort Study

    Article • Arthritis Care & Research, March 2025, Wiley

    Dr. Dafna D Gladman

  41. Comment on: Impact of baseline proteinuria level on long-term outcomes in lupus nephritis: Reply

    Article • Rheumatology, March 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  42. GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets

    Article • Nature Communications, February 2025, Springer Science + Business Media

    Dr. Dafna D Gladman

  43. Identified genetic locus for longitudinal disease activity in adults with systemic lupus erythematosus

    Article • Rheumatology, February 2025, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  44. Degenerative Disc Disease in Young Adults With Psoriatic Arthritis

    Article • The Journal of Rheumatology, February 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  45. Second Trimester Kidney Function and Adverse Pregnancy Outcomes among Patients with Lupus

    Article • Kidney360, February 2025, Wolters Kluwer Health

    Dr. Dafna D Gladman

  46. Single-cell RNA sequencing of circulating immune cells supports inhibition of TNFAIP3 and NFKBIA translation as psoriatic arthritis biomarkers

    Article • Frontiers in Immunology, February 2025, Frontiers

    Dr. Dafna D Gladman

  47. Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies

    Article • The Journal of Rheumatology, February 2025, The Journal of Rheumatology

    Dr. Dafna D Gladman

  48. Identifying characteristics for a cost-effective psoriatic arthritis biomarker test: a development-focused health technology assessment

    Article • International Journal of Technology Assessment in Health Care, January 2025, Cambridge University Press

    Dr. Dafna D Gladman

  49. Long-term tofacitinib efficacy and safety in psoriatic arthritis with or without prior biologic DMARD exposure: a post hoc analysis

    Article • Rheumatology Advances in Practice, January 2025, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  50. Lupus nephritis II: Treatment and monitoring

    Article • January 2025, Elsevier

    Dr. Dafna D Gladman

  51. Lupus nephritis: Biomarkers

    Article • January 2025, Elsevier

    Dr. Dafna D Gladman

  52. Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

    Article • Arthritis Research & Therapy, December 2024, Springer Science + Business Media

    Dr. Dafna D Gladman

  53. Advances in the management of psoriatic arthritis in adults

    Article • BMJ, November 2024, BMJ

    Dr. Dafna D Gladman

  54. Interferon-α as a biomarker to predict renal outcomes in lupus nephritis

    Article • Lupus Science & Medicine, November 2024, BMJ

    Dr. Zahi Touma, Dr. Dafna D Gladman

  55. Chronic kidney disease in patients with psoriatic arthritis: a cohort study

    Article • RMD Open, November 2024, BMJ

    Dr. Dafna D Gladman

  56. Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial

    Article • Annals of the Rheumatic Diseases, November 2024, Elsevier

    Dr. Dafna D Gladman

  57. Impact of baseline proteinuria level on long-term outcomes in lupus nephritis

    Article • Rheumatology, October 2024, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  58. OMERACT systemic lupus erythematosus domain survey

    Article • Seminars in Arthritis and Rheumatism, October 2024, Elsevier

    Prof. Luís Sousa Ines, Dr. Dafna D Gladman

  59. Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort

    Article • Annals of the Rheumatic Diseases, October 2024, Elsevier

    Dr. Dafna D Gladman

  60. Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status

    Article • Rheumatology and Therapy, September 2024, Springer Science + Business Media

    Dr. Dafna D Gladman

  61. Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials

    Article • Rheumatology and Therapy, September 2024, Springer Science + Business Media

    Dr. Dafna D Gladman

  62. Bimekizumab provided rapid improvements in patient-reported symptoms and health-related quality of life in patients with active psoriatic arthritis: pooled 16-week results from two phase 3 studies

    Article • RMD Open, September 2024, BMJ

    Dr. Dafna D Gladman

  63. Candidate Biomarkers for Response to Treatment in Psoriatic Disease

    Article • The Journal of Rheumatology, September 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  64. Short and Long-Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

    Article • Rheumatology, August 2024, Oxford University Press (OUP)

    Dr. Zahi Touma, Dr. Dafna D Gladman

  65. Full Guidelines—From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis

    Article • Journal of the American Academy of Dermatology, August 2024, Elsevier

    Dr. Dafna D Gladman

  66. Treatment controversies in spondyloarthritis and psoriatic arthritis: focus on biologics and targeted therapies

    Article • Expert Review of Clinical Immunology, July 2024, Taylor & Francis

    Dr. Dafna D Gladman

  67. Composite Outcome Measures for Psoriatic Arthritis: OMERACT and 3 and 4 Visual Analog Scale Progress in 2023

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  68. Prologue: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 Annual Meeting

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  69. The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Celebrates Its 20th Anniversary

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  70. GRAPPA 2023 Collaborative Research Network Meeting

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  71. GRAPPA 2023: Major Projects, Key Advances, and Milestones

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  72. Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis

    Article • The Journal of Rheumatology, July 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  73. Phase 2 Trial of Deucravacitinib in Psoriatic Arthritis: Biomarkers Associated With Disease Activity, Pharmacodynamics, and Clinical Responses

    Article • Arthritis & Rheumatology, July 2024, Wiley

    Dr. Dafna D Gladman

  74. Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation

    Article • Journal of the American Academy of Dermatology, June 2024, Elsevier

    Dr. Dafna D Gladman

  75. Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-year results from two phase 3 studies

    Article • Rheumatology, May 2024, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  76. Anti-KIF20B autoantibodies are associated with cranial neuropathy in systemic lupus erythematosus

    Article • Lupus Science & Medicine, April 2024, BMJ

    Dr. Dafna D Gladman

  77. TYK2: an emerging therapeutic target in rheumatic disease

    Article • Nature Reviews Rheumatology, March 2024, Springer Science + Business Media

    Dr. Dafna D Gladman

  78. Use of Apremilast to Achieve Psoriatic Arthritis Treatment Goals and Satisfaction at 1 Year in the Canadian Real-World APPRAISE Study

    Article • Rheumatology and Therapy, February 2024, Springer Science + Business Media

    Dr. Dafna D Gladman

  79. Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA)

    Article • The Journal of Rheumatology, February 2024, The Journal of Rheumatology

    Dr. Dafna D Gladman

  80. Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL

    Article • RMD Open, February 2024, BMJ

    Dr. Dafna D Gladman

  81. Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment

    Article • Frontiers in Immunology, January 2024, Frontiers

    Dr. Dafna D Gladman

  82. Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis

    Article • Rheumatology, January 2024, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  83. Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis

    Article • Lupus Science & Medicine, January 2024, BMJ

    Dr. Zahi Touma, Dr. Dafna D Gladman

  84. BASDAI versus ASDAS in evaluating axial involvement in patients with psoriatic arthritis: a pooled analysis of two phase 3 studies

    Article • Rheumatology Advances in Practice, January 2024, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  85. Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis

    Article • RMD Open, January 2024, BMJ

    Dr. Dafna D Gladman

  86. Derivation and Internal Validation of a Disease‐Specific Cardiovascular Risk Prediction Model for Patients With Psoriatic Arthritis and Psoriasis

    Article • Arthritis & Rheumatology, December 2023, Wiley

    Dr. Dafna D Gladman

  87. Different Immunologic Profiles are Associated with Distinct Clinical Phenotypes in Longitudinally Followed Systemic Lupus Erythematosus Patients

    Article • Arthritis & Rheumatology, December 2023, Wiley

    Dr. Zahi Touma, Dr. Dafna D Gladman

  88. Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial

    Article • RMD Open, November 2023, BMJ

    Dr. Dafna D Gladman

  89. Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention

    Article • Arthritis & Rheumatology, October 2023, Wiley

    Dr. Dafna D Gladman

  90. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update

    Article • Annals of the Rheumatic Diseases, October 2023, BMJ

    Prof. Luís Sousa Ines, Dr. Dafna D Gladman

  91. Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study

    Article • Rheumatology and Therapy, October 2023, Springer Science + Business Media

    Dr. Dafna D Gladman

  92. Incidence and predictors of demyelinating disease in spondyloarthritis: data from a longitudinal cohort study

    Article • Rheumatology, October 2023, Oxford University Press (OUP)

    Dr. Dafna D Gladman

  93. Psoriatic Arthritis and COVID-19: Patient Perspectives in a Large Psoriatic Arthritis Cohort

    Article • The Journal of Rheumatology, September 2023, The Journal of Rheumatology

    Dr. Dafna D Gladman

  94. Patient clusters identified by machine learning from a pooled analysis of the clinical development programme of secukinumab in psoriatic arthritis, ankylosing spondylitis and psoriatic arthritis with axial manifestations

    Article • Clinical and Experimental Rheumatology, June 2023, Clinical and Experimental Rheumatology

    Dr. Dafna D Gladman

  95. The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2

    Article • Therapeutic Advances in Musculoskeletal Disease, January 2023, SAGE Publications

    Dr. Dafna D Gladman

  96. Psoriatic arthritis

    Article • F1000Research, September 2019, Faculty of 1000, Ltd.

    Dr. Dafna D Gladman, Vanessa Ocampo

  97. Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis

    Article • PLOS One, February 2019, PLOS

    Dr. Dafna D Gladman

  98. Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis

    Article • Annals of the Rheumatic Diseases, November 2018, Elsevier

    Dr. Dafna D Gladman

  99. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors

    Article • Lupus, May 2017, SAGE Publications

    Dr. Dafna D Gladman

  100. Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies

    Article • Open Access Rheumatology Research and Reviews, December 2016, Dove Medical Press

    Professor Murray B Urowitz, Dr. Dafna D Gladman

  101. Recent advances in understanding and managing psoriatic arthritis

    Article • F1000Research, November 2016, Faculty of 1000, Ltd.

    Dr. Dafna D Gladman

  102. Evaluation of Clinical Outcomes and Renal Vascular Pathology among Patients with Lupus

    Article • Clinical Journal of the American Society of Nephrology, March 2012, American Society of Nephrology

    Professor Murray B Urowitz, Dr. Dafna D Gladman

  103. Reply

    Article • Arthritis Care & Research, December 2010, Wiley

    Dr. Dafna D Gladman

  104. Reply

    Article • Arthritis Care & Research, April 2010, Wiley

    Dr. Dafna D Gladman

  105. Targeted therapy for psoriatic arthritis

    Article • Nature Reviews Rheumatology, May 2009, Springer Science + Business Media

    Dr. Dafna D Gladman

  106. Psoriatic arthritis

    Article • Dermatologic Therapy, January 2009, Wiley

    Dr. Dafna D Gladman

  107. Can we identify psoriatic arthritis early?

    Article • Current Rheumatology Reports, December 2008, Springer Science + Business Media

    Dr. Dafna D Gladman

  108. Axial disease in psoriatic arthritis

    Article • Current Rheumatology Reports, November 2007, Springer Science + Business Media

    Dr. Dafna D Gladman

  109. Traditional and Newer Therapeutic Options for Psoriatic Arthritis

    Article • Drugs, January 2005, Springer Science + Business Media

    Dr. Dafna D Gladman

  110. Psoriatic arthritis

    Article • Dermatologic Therapy, October 2004, Hindawi Publishing Corporation

    Dr. Dafna D Gladman

  111. Diagnosis and Management of Psoriatic Arthritis

    Article • Drugs, January 2002, Springer Science + Business Media

    Dr. Dafna D Gladman

  112. Reply

    Article • Arthritis & Rheumatism, January 1999, Wiley

    Dr. Dafna D Gladman

  113. Assessing lupus

    Article • Arthritis & Rheumatism, December 1998, Wiley

    Dr. Dafna D Gladman

  114. Psoriatic Arthritis

    Article • BioDrugs, January 1998, Springer Science + Business Media

    Dr. Dafna D Gladman

  115. Psoriatic arthropathy

    Article • Current Opinion in Orthopedics, December 1995, Wolters Kluwer Health

    Dr. Dafna D Gladman

  116. Psoriatic arthritis

    Article • Baillière s Clinical Rheumatology, May 1995, Elsevier

    Dr. Dafna D Gladman

  117. Natural history of psoriatic arthritis

    Article • Baillière s Clinical Rheumatology, June 1994, Elsevier

    Dr. Dafna D Gladman

  118. Toward unraveling the mystery of psoriatic arthritis

    Article • Arthritis & Rheumatism, July 1993, Wiley

    Dr. Dafna D Gladman

  119. Reply

    Article • Arthritis & Rheumatism, June 1993, Wiley

    Dr. Dafna D Gladman

  120. Assessment of disease activity in lupus

    Article • Transfusion Science, April 1992, Elsevier

    Dr. Dafna D Gladman

  121. Psoriatic arthritis

    Article • Current Opinion in Rheumatology, August 1990, Wolters Kluwer Health

    Dr. Dafna D Gladman

  122. Epidemiology

    Article • Springer Science + Business Media

    Dr. Dafna D Gladman

  123. Psoriatic Arthritis

    Article • Springer Science + Business Media

    Dr. Dafna D Gladman